Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX<sup>®</sup>) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.

Medicines (Basel) · 2018 · PMC6163235 · PMID 29933552

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Intriguingly, there was a significant increase in the hand CPT of patients after Sativex ® , and a significant percentage reduction in abnormal CDT after therapy, although the difference did not reach statistical significance between patients before and after treatment.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.